Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 18:17 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Anxiety-mediated Impairments in Large Elastic Artery Function and the Autonomic Nervous System
NCT03109795 · University of Iowa · PHASE4 · terminated · last registry update 2024-07-29 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Funding ended” | – | Registry record, University of Iowa |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SLC12A3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-07-29Results posted on the registry: Prevencion, Hydrochlorothiazide + Amlodipine (NCT02373163)
- 2025-07-22Results posted on the registry: University of Alabama at Birmingham, Perindopril + Losartan (NCT03295734)
- 2025-07-09Results posted on the registry: Alnylam Pharmaceuticals, Indapamide + Amlodipine (NCT05103332)
- 2025-06-12Results posted on the registry: Eurofarma Laboratorios S.A., Chlorthalidone 25 mg + amiloride hydrochloride 5 mg + Higroton® Laboratório Novartis (NCT01191450)
- 2025-06-05Results posted on the registry: Stanford University, Metolazone + Placebo (NCT04542304)
- 2025-06-05Also stopped (terminated): Stanford University, Metolazone + Placebo (NCT04542304)
- 2025-06-03Results posted on the registry: George Medicines PTY Limited, Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg + telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg (NCT04518293)
- 2025-06-03Results posted on the registry: George Medicines PTY Limited, Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg + Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg (NCT04518306)
- 2025-03-21Results posted on the registry: Pfizer, Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Viatris + Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Neolpharma. (NCT06205407)
- 2025-02-14Also stopped (terminated): Stadtspital Zürich, Furosemide + Metolazone (NCT05986773)
- 2024-10-10Results posted on the registry: University of New Mexico, Treatment of Furosemide + Hydrochlorothiazide + Treatment of Furosemide + Metolazone (NCT00690521)
- 2024-07-15Phase 3 first posted: Shenzhen Salubris Pharmaceuticals Co., Ltd., Allisartan Isoproxil/Sustained-Release Indapamide + Allisartan Isoproxil (NCT06500689)
- 2024-05-22Results posted on the registry: VA Office of Research and Development, Hydrochlorothiazide (HCTZ) + Chlorthalidone (CTD) (NCT02185417)
- 2024-02-28Results posted on the registry: Penn State University, Captopril Pill + Enalapril Pill (NCT03179163)
- 2024-02-28Also stopped (terminated): Penn State University, Captopril Pill + Enalapril Pill (NCT03179163)
- 2024-02-01Results posted on the registry: Insel Gruppe AG, University Hospital Bern, Placebo oral capsule + 12.5 mg hydrochlorothiazide (NCT03057431)
- 2023-12-12Phase 3 first posted: Johannes Grand, Acetazolamide + Metolazone 2.5 MG (NCT06166654)
- 2023-10-25Results posted on the registry: University of Texas Southwestern Medical Center, Potassium Magnesium Citrate (KMgCit) + Potassium Chloride (KCl) (NCT02665117)
- 2023-10-24Also stopped (terminated): Novartis, Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1 + Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2 (NCT00170950)
- 2023-10-13Also stopped (withdrawn): Northwestern University, Amlodipine Besylate + Chlorthalidone (NCT05275907)
- 2023-09-22Results posted on the registry: Washington University School of Medicine, QUARTET LDQT + Candesartan (NCT03640312)
- 2023-08-21Results posted on the registry: Tulane University School of Medicine, amlodipine, hydralazine, terazosin or hydrochlorothiazide (NCT02046395)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision